

# 澳大利亚生物技术协会 澳大利亚医疗技术公司名录



## 公司介绍

公司名称: Regeneus Ltd

主要联系人姓名: Sandra McIntosh

主要联系人职务: 企业秘书及投资者关系主管

公司网址: [www.regeneus.com.au](http://www.regeneus.com.au)

公司地址: 25 Bridge Street, Pymble, NSW 2073

公司已上市

## 公司简介

Regeneus 有限公司(澳交所股票代码: RGS) 是一家处于临床阶段的再生医学公司。Regeneus 通过开发一系列细胞疗法的专利, 解决人类和兽医健康市场上明显未被满足的医疗需求, 尤其针对肌肉骨骼类疾病、肿瘤、皮肤科疾病。

Regeneus 目前正开发 4 项用于治疗人类疾病且处于不同开发阶段的治疗方法和产品, 其中即将开展首次人体试验的有两项: Progenza 是一种现有异体脂肪干细胞疗法, 用于治疗肌肉骨骼类疾病; 而 RGSH4K 是一款人体自体同源、适用于治疗多种癌症类型的癌症疫苗。Regeneus 还开发出一款以干细胞为基底、抗皮肤发炎的乳霜产品, 而 HiQCell 则是一项针对肌肉骨骼疾病的自体疗法。Regeneus 有两项针对动物疾病的治疗产品: CryoShot 是一款正在临床试验阶段, 用于治疗犬类和马类肌肉骨骼类疾病的现有异体脂肪干细胞疗法, 而 Kvax 则是一款正在营销推广期的自体化癌症疫苗。

## 关键技术或领先技术

Regeneus 应用来源于自体 and 异体、由脂肪组织衍生出的干细胞作治疗。Regeneus 有一款适用于人体和动物的自体癌症疫苗, 并有一款由干细胞分泌物制成的护肤霜, 该护肤霜可用于治疗人体皮肤发炎的症状。

## 类别

其他: 干细胞疗法

## 关键技术或领先技术的发展阶段

临床试验中阶段

产品已经上市

## 合作机会

Regeneus 寻求投资以及多款产品全球认证的机会。

# Directory of Australian medtech companies



## COMPANY DETAILS

**Company name:** Regeneus Ltd

**Key contact name:** Sandra McIntosh

**Job title of key contact:** Company Secretary and Investor Relations

**Company website address:** [www.regeneus.com.au](http://www.regeneus.com.au)

**Company address:** 25 Bridge Street, Pymble, NSW 2073

**The company is Listed.**

## ABOUT THE COMPANY

Regeneus Ltd (ASX: RGS) is a clinical-stage regenerative medicine company developing a patented portfolio of cell therapies to address significant unmet medical needs in the human and veterinary health markets with a focus on musculoskeletal disease, oncology and dermatology.

The company has four therapies targeting human conditions in various stages of development including two products approaching first-in-human Phase 1: Progenza is an allogeneic off-the-shelf adipose stem cell therapy to treat musculoskeletal conditions and RGS4K is a human autologous personalised therapeutic cancer vaccine to treat a wide range of cancer types. The company has developed a stem cell based cream to targeting inflammatory skin conditions and HiQCell is a commercial autologous therapy for the treatment of musculoskeletal conditions. The company has two therapies targeting animal conditions: CryoShot is a clinical-phase allogeneic off-the-shelf adipose stem cell therapy for the treatment of canine and equine musculoskeletal conditions and Kvax is a commercial autologous personalised therapeutic cancer vaccine in marketing trials.

## KEY OR LEAD TECHNOLOGY

Stem cell therapies sourcing from adipose derived tissue, both autologous and allogeneic. We also have an autologous cancer vaccine for both animals and humans. We also have a stem cell secretions cream which targets inflammatory skin conditions for humans.

**Category**

**Other:** Stem cell therapy

**Point of development of key or lead technology**

In clinical trials

Product on the market

**OPPORTUNITIES SOUGHT**

Investment opportunities and global licensing opportunities for various products.